Vigilance and Equanimity are the Needs of the Hour Executive Summary Key Trends in the Pharmaceutical and Biotechnology Industry The challenges posed by reducing margins, expiring patents, increasing compliance costs, and regulatory thrusts because of delayed approvals are forcing participants in the pharmaceutical and biotechnology industry to restructure and streamline strategies to cease the diminishing profitability and increase the returns from research and development (R&D). Though the returns from the pharmaceutical and biotechnology (pharma and biotech) industry have been on the decline compared to previous years, they are better compared to the performance of other industries. Key Trends- Global decline in private equity and venture capital (PEVC) deals in healthcare (HC) is reflected in the decline of PEVC deals in the pharma and biotech industry.- Venture capital (VC) deals in both the pharmaceutical and biotechnology sectors witnessed a decline in average deal value over the years, with an increase in rounds of investment.- The deal value analysis showed a preference for mid-sized deals in both private equity (PE) and VC investment.- Geographic analysis revealed the United States represents the largest share of deals, and the sectorial preference of investors varied across geographies.- The strong comeback of initial public offering (IPO) in 2013 sends a positive outlook for investment in the pharma and biotech industry.
